Psychosis and Type 2 Diabetes Study (PODS)

NCT ID: NCT05496907

Last Updated: 2022-12-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-22

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

People with severe mental illness (SMI), defined as psychotic and bipolar disorders, die 17-20 years earlier than the general population, the most common cause of death being cardiovascular diseases (CVD). The major contributor to CVD mortality in SMI is the increased prevalence of type 2 diabetes (T2D) compared to the general population. T2D is a paradigm of a single condition that progresses to multiple conditions. T2D requires annual reviews of 9 diabetes care processes and for patients to adopt multiple self-care tasks to prevent diabetes complications. The 9 diabetes care processes outlined by the NICE guidelines include: 3-6 monthly blood glucose measurement (HbA1c) with targets; blood pressure measurements and targets; annual blood cholesterol measurement; kidney function testing with urinary albumin; kidney function testing with serum creatinine; weight check; smoking status; diabetes annual eye screening; and annual foot examination.

Previous research has focused on upskilling mental health professionals or link workers in diabetes care, however, a primary care led focus to support individuals with T2D and SMI has not been investigated. This is an interventional study in Lambeth south London testing a new model of care for people with SMI and T2D that is led by the community DSN in collaboration with the PN and mental health team within the Hills Brook and Dales Primary Care Network (PCN). StockWELL PCN participants will act as controls. Participants will complete 7 validated questionnaires, a physical examination including a blood test and urine sample and a brief interview either face to face in their GP surgery. The intervention group will be invited to a clinic run by a DSN. Baseline measures will be repeated after 6 months in both groups. An exit interview will be conducted to determine participants thoughts on the intervention. This project has been funded by the Burdett Trust for Nursing.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The research team will approach the potential participants by contacting them directly and sending a invite letter and the participant information sheet to them by post. This contact is in accordance with consent for future contact given as part of a previous study (IRAS: 307600). Local staff resource/direct care team are not involved in the identification or recruitment of participants in this current application. If the participant contacts the research team, an appointment will be made to complete the consent process, this will occur either over the phone or face to face, depending on the participants' preference.

This will be an interventional study with a non-randomised control group of integrated nurse-led intervention with a 6 month follow up. Patients that belong to GP surgeries in the hills, brook and dales PCN, will automatically be put in the intervention arm, whereas patients who belong to a GP in the StockWELL PCN will be placed in the control group. The investigators will aim to recruit 30 participants in each group, so 60 in total.

After the participants consent, they will be asked to complete 7 validated questionnaires (Diabetes Distress Scale, International Physical Activity Questionnaire, Quality of Life Scale, Global Assessment of Functioning, Alcohol Usage Disorders Identification Test, Drug Abuse Screening Test and Empower Up). These can be found in the case report form, and participants answers will be recorded in the case report form. An Interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. This will take place either face to face at the participants GP surgery or over the phone, depending on the participants preference.

A physical assessment will be conducted including Blood pressure (mmHg), BMI (m/kg2), Urinary ACR (mg/mmol), and Blood Tests for HbA1c (mmol/mol), Glucose test (mmol/L), Total Cholesterol (mmol/mol), Renal Function (mL/min), this will be completed at the participants GP surgery by the direct care team.

This information will be written in a case report form and will kept in a locked filling cabinet in James Clerk Maxwell Building, King's College London (KCL). Data from the form will be entered onto the research REDCAP database by the research team.

Intervention group:

Participants from GP practices within the Hills Brooks and Dales PCN will be invited to face to face or virtual clinics with the DSN and PN. During the appointments the DSN and PN will try and help improve the individual's diabetes control by;

* The patients and health professionals will identify specific and measurable goals to work towards, which will be monitored and form part of a care plan.
* Support the patients' self-management for example medication taking.
* Carry out missing care processes or refer the patient to have them done.
* Discuss strategies on how to optimise a healthy lifestyle and how to improve glycaemic control.
* Sign-post patients to activities and support groups that may benefit their mental and physical wellbeing.
* Encourage patients to engage in regular reviews with DSN/PN to monitor progress and to promote proactive treatment amendments.

Control group:

Participants from 5 GPs in the StockWELL PCN will be invited to join the study by the research team. They will receive their usual diabetes and mental health care. If the research team discover any missing care processes, their care team will be made aware.

Follow-up:

The same measures that were completed at the beginning will be re-assessed again at 6 months, these include; 7 validated questionaries (Diabetes Distress Scale, International Physical Activity Questionnaire, Quality of Life Scale, Global Assessment of Functioning, Alcohol Usage Disorders Identification Test, Drug Abuse Screening Test and Empower Up. An Interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. This will take place either face to face at the participants GP surgery or over the phone, depending on the participants preference.

However, the investigators will also include the Patients Global Impression of Change to measure the overall change in quality of life since beginning the study from the patients' perspective.

A physical assessment will be conducted including Blood pressure (mmHg), BMI (m/kg2), Urinary ACR (mg/mmol), and Blood Tests for HbA1c (mmol/mol), Glucose test (mmol/L), Total Cholesterol (mmol/mol), Renal Function (mL/min), this will be completed at the participants GP surgery by the research team.

To evaluate the patients' experience of this new care pathway exit interviews with participants in the intervention group will be conducted by the research team either over the phone or face to face at the participants GP surgery, depending on their preference. This will approximately take 30 minutes. The interviews will be audio recorded and transcribed before being qualitatively analysed by the research team.

If the participant lacks capacity to consent, the investigators will ask them again in a few weeks to see whether capacity has been restored. If the participant still lacks capacity, their clinical team will be asked if there is a potential personal or professional consultee. The research team will contact this person and ask if they are happy to consent on the participants' behalf.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Severe Mental Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

After the participants consent, they will be asked to complete 7 validated questionnaires. An interview will also take place to determine severity of psychiatric symptoms using the Brief Psychiatric Rating Scale. A physical assessment will be conducted including Blood pressure, BMI and Blood Tests for HbA1c, Glucose test, Total Cholesterol, Renal Function.

Participants in the intervention arm will see the diabetes nurse up to 10 times, during these sessions motivational interviewing will be used to discuss areas to improve, goal setting and action planning. Participants and the nurse will collaboratively discuss practical strategies to improve their HbA1c, blood pressure, cholesterol, BMI and mental health.

The same measures that were completed at the beginning will be re-assessed again at 6 months.

Group Type EXPERIMENTAL

Diabetes specialist nurse-led collaborative care intervention

Intervention Type BEHAVIORAL

10 sessions with a diabetes nurse to help improve physical and mental health outcomes

Control

Participants will be asked to complete the same 7 validated questionnaires, the brief psychiatric rating scale and a physical health assessment at the start. The will continue to receive standard care from their usual care professionals. The same measures that were completed at the beginning will be re-assessed again at 6 months.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diabetes specialist nurse-led collaborative care intervention

10 sessions with a diabetes nurse to help improve physical and mental health outcomes

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants will need to have a diagnosis of type 2 diabetes and bipolar affective disorder or psychosis.
* Capacity to consent: if the participant does not currently have capacity to consent, we will ask them again in a few weeks to see whether capacity has been restored. If the participant still lacks capacity, they will be asked to elect a personal consultee nominee to consent on their behalf. If there is not anyone suitable, we will ask their clinical team to nominate a professional consultee. The research team will then contact this person and ask if they are happy to consent on the participants' behalf.
* Participants must be 18 years or older.

Exclusion Criteria

* Adults without an SMI diagnosis.
* Adults with SMI and other types of diabetes, e.g. type 1 diabetes or gestational diabetes (as different management).
* Self-reported pregnancy status (as would require intensive management in a dedicated clinic).
* Dementia.
* Organic psychosis.
* Moderate-severe learning disabilities
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King's College London

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kirsty Graham

Role: PRINCIPAL_INVESTIGATOR

King's College London University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Herne Hill Group Practice

London, , United Kingdom

Site Status

Knight's Hill

London, , United Kingdom

Site Status

Brixton Hill

London, , United Kingdom

Site Status

Northwood Group Practice

London, , United Kingdom

Site Status

Binfield Road Practice

London, , United Kingdom

Site Status

Springfield Medical Centre

London, , United Kingdom

Site Status

Beckett House

London, , United Kingdom

Site Status

Grantham Practice

London, , United Kingdom

Site Status

Stockwell Group Practice

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

289799

Identifier Type: -

Identifier Source: org_study_id